DEC 0 2 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER:

10/080,979

FILING DATE:

02/22/2002

FIRST NAMED INVENTOR:

Phillip Dan Cook

ART UNIT:

1635

EXAMINER NAME:

Amy Hudson Bowman

ATTORNEY DOCKET NUMBER:

ISIS-5028

TITLE:

METHOD OF USING MODIFIED

OLIGONUCLEOTIDES FOR HEPATIC

DELIVERY

I certify that this communication is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Laura Eames

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Under 37 C.F.R. §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 C.F.R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

Serial No.: 10/080,979 Docket No.: ISIS-5028

within three months of the filing date of the application, or date of entry into					
the national stage of an international application, or before the mailing date of a					
first office action on the merits, whichever event last occurred;					
before the mailing of a first official action after filing of a request for					
continued examination (RCE) under 37 C.F.R. § 1.114;					
after three months of the filing date of this national application or the date of					
entry of the national stage in an international application, or after the mailing date					
of the first official action on the merits, whichever event last occurred, but before					
that mailing date of the first office action to occur of either: (1) a final action					
under 37 C.F.R. § 1.113; or (2) an action that otherwise closes prosecution in the					
application, and:					
attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for					
submission of this Information Disclosure Statement under 37 C.F.R. §					
1.97(c); OR					
Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:					
each item of the information contained in this Information					
Disclosure Statement was first cited in a communication from a					
foreign patent office in a counterpart foreign application not more					
than three months prior to the filing of this Statement;					
OR					
no item of information contained in this Information Disclosure					
Statement was cited in a counterpart foreign application and, to the					
knowledge of the person signing this certification after making					
reasonable inquiry, no item of information contained in this					
Statement was known to any individual designated under 37 C.F.R.					
§ 1.56(c) more than three months prior to the filing of this					
Statement.					
on or before the payment of the issue fee but after the mailing date of the first					
to occur of either: (1) a final action under 37 C.F.R. § 1.113; (2) a notice of					
allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes					
prosecution in the application, and:					

Serial No.: 10/080,979 Docket No.: ISIS-5028

Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:
each item of information contained in this Information
Disclosure Statement was cited in a communication from a foreign
patent office in a counterpart foreign application not more than
three months prior to the filing of this statement;
OR
no item of information contained in this Information Disclosure
Statement was cited in a counterpart foreign application and, to the
knowledge of the person signing this certification after making
reasonable inquiry, no item of information contained in this
Statement was known to any individual designated under 37 C.F.R
§ 1.56(c) more than three months prior to the filing of this
Statement. AND
attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for
submission of this Information Disclosure Statement under 37 C.F.R. §
1.97(c); OR
after the payment of the issue fee. Applicant requests that the information
contained in this Information Disclosure Statement be placed in the file according
to 37 C.F.R. § 1.97(i), although the information may not be considered by the
USPTO.
Enclosed is a copy of each listed reference that may be material to the examination of
this application, and for which there may be a duty to disclose.
☐ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior
application No. , filed on , and the references cited therein are hereby
referenced, but are not required to be provided in this application under 37 C.F.R. §
1.98(d).
This application was filed after June 30, 2003. Therefore, pursuant to the waiver of
the requirements under 37 C.F.R. § 1.98(a)(2)(i), copies of each U.S. Patent and each
U.S. Patent Application Publication are not required to be submitted. Copies of any
foreign patent documents and non-patent literature cited herein are enclosed.

Serial No.: 10/080,979 Docket No.: ISIS-5028

Each item of information contained in this Information Disclosure Statement was
cited in the communication from a foreign patent office in a counterpart application, and
the communication was not received by any individual designated in 37 C.F.R. § 1.56(c
more than thirty days prior to the filing of this Information Disclosure Statement 37
C.F.R. § 1.704(d).
Applicant submits that no fee is required for the consideration of this Information
Disclosure Statement. However, if a fee is due, the Commissioner is hereby authorized

Dated: Nov 30,2005

Consideration of the listed references and favorable action are solicited.

to charge Deposit Account No 500252 referencing case number

Respectively Submitted,

Colleen J. McKiernan, Ph.D.

Registration No.: 48,570 Isis Pharmaceuticals, Inc. 1896 Rutherford Road Carlsbad, CA 92008

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

O.S. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office, o.S. DET ARTIMETY OF Continuence of St. Faterit and Trademark Office of St. Faterit and Trademark Off

PROTESTICE for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/080,979		
				Filing Date	02/22/2002		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Phillip Dan Cook		
				Art Unit	1635		
(Use as many sheets as necessary)				Examiner Name	Amy Hudson Bowman		
Sheet	1	of	1	Attorney Docket Number	ISIS-5028		

DEC 0 2 2005

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document		
	PL	US-6,753,423	06-22-2004	Isis Pharmaceuticals, Inc.		
	PM	US-6,783,931	08-31-2004	Isis Pharmaceuticals, Inc.		
-9-						
				2		
			·			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)				
	l				1	

Examiner Signature	Date Considered	
		L

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

WIPO Standard S1. 16 if possible." Applicant is to place a check mark here it English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.